Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States.

Imane Abou Dalle Hagop M KantarjianJan BurgerZeev E EstrovMaro OhanianSrdan VerstovsekFarhad RavandiGautam BorthakurGuillermo Garcia-ManeroElias JabbourJorge Cortes

Published in: Cancer medicine (2019)

A change from original to generic imatinib appears to maintain efficacy and be generally safe. More patients and longer follow-up are required to confirm these observations.

Keyphrases

chronic myeloid leukemia
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
patient reported